$ATNM
Actinium Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000121390022072371 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $45.00K $233.0K
YoY Change -100.0% -80.69%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.958M $3.073M $1.994M
YoY Change 49.08% 54.11% 9.26%
% of Gross Profit
Research & Development $7.333M $6.771M $4.708M
YoY Change 35.4% 43.82% 24.29%
% of Gross Profit
Depreciation & Amortization $161.0K $221.0K $133.0K
YoY Change 17.52% 66.17% 19.82%
% of Gross Profit
Operating Expenses $11.29M $9.844M $6.702M
YoY Change 39.9% 46.88% 19.4%
Operating Profit -$9.799M -$6.469M
YoY Change 51.48%
Interest Expense $644.0K $325.0K $46.00K
YoY Change 1594.74% 606.52% -36.99%
% of Operating Profit
Other Income/Expense, Net $325.0K $46.00K
YoY Change 606.52%
Pretax Income -$10.65M -$9.474M -$6.423M
YoY Change 32.92% 47.5% 15.94%
Income Tax
% Of Pretax Income
Net Earnings -$10.65M -$9.474M -$6.423M
YoY Change 32.92% 47.5% 15.94%
Net Earnings / Revenue -21053.33% -2756.65%
Basic Earnings Per Share -$0.38 -$0.30
Diluted Earnings Per Share -$0.42 -$0.38 -$298.2K
COMMON SHARES
Basic Shares Outstanding 25.48M shares 25.18M shares 21.54M shares
Diluted Shares Outstanding 25.16M shares 21.54M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $108.9M $111.8M $82.03M
YoY Change 39.93% 36.31% 70.07%
Cash & Equivalents $108.9M $111.8M $82.03M
Short-Term Investments
Other Short-Term Assets $2.032M $1.608M $1.229M
YoY Change 5.83% 30.84% 29.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $110.9M $113.4M $83.26M
YoY Change 39.11% 36.23% 69.3%
LONG-TERM ASSETS
Property, Plant & Equipment $604.0K $635.0K $776.0K
YoY Change 77.65% -18.17% -14.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $302.0K $300.0K $442.0K
YoY Change -32.13% 0.23%
Total Long-Term Assets $3.250M $3.393M $1.218M
YoY Change 408.61% 178.57% -9.58%
TOTAL ASSETS
Total Short-Term Assets $110.9M $113.4M $83.26M
Total Long-Term Assets $3.250M $3.393M $1.218M
Total Assets $114.2M $116.8M $84.48M
YoY Change 42.05% 38.28% 67.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.13M $7.869M $3.773M
YoY Change 83.02% 108.56% -10.66%
Accrued Expenses $494.0K $386.0K $333.0K
YoY Change 101.63% 15.92% -0.6%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $4.000K $4.000K $84.00K
YoY Change -93.55% -95.24% 0.0%
Total Short-Term Liabilities $10.63M $8.350M $4.190M
YoY Change 55.38% 99.28% -10.47%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.000K $4.000K
YoY Change -100.0% -75.0% -95.4%
Other Long-Term Liabilities $37.08M $37.21M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $37.08M $37.21M $4.000K
YoY Change 1236000.0% 930175.0% -99.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.63M $8.350M $4.190M
Total Long-Term Liabilities $37.08M $37.21M $4.000K
Total Liabilities $47.71M $45.56M $4.194M
YoY Change 597.22% 986.34% -17.76%
SHAREHOLDERS EQUITY
Retained Earnings -$288.8M -$278.1M
YoY Change 12.91%
Common Stock $26.00K $25.00K
YoY Change 18.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.48M $71.26M $80.29M
YoY Change
Total Liabilities & Shareholders Equity $114.2M $116.8M $84.48M
YoY Change 42.05% 38.28% 67.2%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$10.65M -$9.474M -$6.423M
YoY Change 32.92% 47.5% 15.94%
Depreciation, Depletion And Amortization $161.0K $221.0K $133.0K
YoY Change 17.52% 66.17% 19.82%
Cash From Operating Activities -$7.778M -$5.715M -$5.588M
YoY Change 53.96% 2.27% 11.89%
INVESTING ACTIVITIES
Capital Expenditures $16.00K -$73.00K -$68.00K
YoY Change 7.35% 750.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$16.00K -$73.00K -$68.00K
YoY Change 7.35% 750.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $5.797M
YoY Change -6202.11%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.893M 1.575M 5.776M
YoY Change 510.86% -72.73% -2611.3%
NET CHANGE
Cash From Operating Activities -7.778M -5.715M -5.588M
Cash From Investing Activities -16.00K -73.00K -68.00K
Cash From Financing Activities 4.893M 1.575M 5.776M
Net Change In Cash -2.901M -4.213M 120.0K
YoY Change -31.76% -3610.83% -102.29%
FREE CASH FLOW
Cash From Operating Activities -$7.778M -$5.715M -$5.588M
Capital Expenditures $16.00K -$73.00K -$68.00K
Free Cash Flow -$7.794M -$5.642M -$5.520M
YoY Change 54.28% 2.21% 10.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2021Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
usd
dei Document Transition Report
DocumentTransitionReport
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity File Number
EntityFileNumber
001-36374
dei Entity Registrant Name
EntityRegistrantName
ACTINIUM PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
74-2963609
dei Entity Address Address Line1
EntityAddressAddressLine1
275 Madison Ave, 7th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10016
dei City Area Code
CityAreaCode
(646)
dei Local Phone Number
LocalPhoneNumber
677-3870
dei Security12b Title
Security12bTitle
Common stock, par value $0.001
dei Trading Symbol
TradingSymbol
ATNM
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
25483306 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111815000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77829000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
394000 usd
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
392000 usd
CY2021Q4 us-gaap Security Deposit
SecurityDeposit
50000 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1214000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1478000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
113423000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
79749000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
440000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
335000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
635000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
340000 usd
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
300000 usd
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
4000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2454000 usd
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
62000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
245000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
241000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
4000 usd
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
58000 usd
CY2022Q3 us-gaap Assets
Assets
116816000 usd
CY2021Q4 us-gaap Assets
Assets
80388000 usd
CY2022Q3 us-gaap Notes Payable Current
NotesPayableCurrent
7869000 usd
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5535000 usd
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
91000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
998000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
386000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
8350000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6840000 usd
CY2022Q3 us-gaap Deferred Revenue
DeferredRevenue
35000000 usd
CY2022Q3 atnm Longterm Operating Lease Obligations Noncurrent
LongtermOperatingLeaseObligationsNoncurrent
2210000 usd
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1000 usd
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
3000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
45561000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
6843000 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25212072 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25212072 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22143974 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22143974 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
25000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
22000 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
349348000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
329271000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278118000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-255748000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
71255000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
73545000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
116816000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80388000 usd
CY2022Q3 us-gaap Sublease Income
SubleaseIncome
45000 usd
CY2021Q3 us-gaap Sublease Income
SubleaseIncome
233000 usd
us-gaap Sublease Income
SubleaseIncome
1030000 usd
us-gaap Sublease Income
SubleaseIncome
1121000 usd
CY2022Q3 us-gaap Revenues
Revenues
45000 usd
CY2021Q3 us-gaap Revenues
Revenues
233000 usd
us-gaap Revenues
Revenues
1030000 usd
us-gaap Revenues
Revenues
1121000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6771000 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4708000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15802000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12615000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3073000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1994000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8041000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5422000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9844000 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
6702000 usd
us-gaap Operating Expenses
OperatingExpenses
23843000 usd
us-gaap Operating Expenses
OperatingExpenses
18037000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9799000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6469000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22813000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-16916000 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
325000 usd
CY2021Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
46000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
443000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
152000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
325000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
46000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
443000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
152000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9474000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6423000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22370000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16764000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.3
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.94
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25164599 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
21539455 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23691218 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20060315 shares
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
61319000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
73545000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
421000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-5129000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
68837000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
425000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
16686000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-7767000 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
78181000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
970000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
1578000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-9474000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71255000 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
376000 usd
CY2021Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
14361000 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-5320000 usd
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
70736000 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
459000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
14319000 usd
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-5021000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80499000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
412000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
5797000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-6423000 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
80285000 usd
us-gaap Net Income Loss
NetIncomeLoss
-22370000 usd
us-gaap Net Income Loss
NetIncomeLoss
-16764000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1816000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1246000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
538000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
387000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-264000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-137000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2334000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-566000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-907000 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
35000000 usd
atnm Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-253000 usd
atnm Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-254000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16422000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15814000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
350000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
133000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-350000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-133000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
48000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
63000 usd
atnm Sales Of Shares Of Common Stock Net Of Costs
SalesOfSharesOfCommonStockNetOfCosts
18264000 usd
atnm Sales Of Shares Of Common Stock Net Of Costs
SalesOfSharesOfCommonStockNetOfCosts
34477000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18216000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
34420000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
34288000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18473000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78221000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63999000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
112509000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82472000 usd
atnm Acquisition Of Equipment Financed By Security Deposit
AcquisitionOfEquipmentFinancedBySecurityDeposit
50000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use of Estimates </b>- The preparation of these unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
atnm Pandemic On Financial Statements
PandemicOnFinancialStatements
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Impact of COVID–19 Pandemic on Financial Statements - </b>The global health crisis caused by the novel coronavirus (“COVID-19”) pandemic and its resurgences has and may continue to negatively impact global economic activity, which, despite progress in vaccination efforts, remains uncertain and cannot be predicted with confidence. In addition, the Omicron variants of COVID-19, including subvariants BA.4 and BA.5, which appear to be the most transmissible variants to date, have spread globally. The full impact of the Omicron variants, or any subsequent variants, cannot be predicted at this time, and could depend on numerous factors, including vaccination rates among the population, the effectiveness of COVID-19 vaccines and boosters against the Omicron variants and subsequent variants and the response by governmental bodies and regulators.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many countries around the world have continued to impose quarantines and restrictions on travel and mass gatherings to slow the spread of the virus. Accordingly, the Company’s ability to continue to operate its business may also be limited. Such events may result in a period of business, supply and drug product manufacturing disruption, and in reduced operations, any of which could materially affect the Company’s business, financial condition and results of operations. In response to COVID-19, the Company implemented hybrid working for its office-based staff, while its research staff has been actively working in its laboratory throughout the pandemic and thus far, has not experienced a significant disruption or delay in its operations as it relates to the clinical development, preclinical research or manufacturing of its drug candidates. Although the Company is adhering to health and safety protocols, an outbreak of COVID-19 at the Company’s facilities could nonetheless cause shutdowns of facilities and a reduction in its workforce, which could cause a disruption or delay in such operations. A continuation or worsening of the levels of market disruption and volatility seen in the recent past could have an adverse effect on the Company’s ability to access capital, which could in the future negatively affect the Company’s liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect the Company’s business and the value of the Company’s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, COVID-19 may result in delays in receiving approvals from local and foreign regulatory authorities, delays in necessary interactions with IRB’s or Institutional Review Boards, local and foreign regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>To date, COVID-19 has not had a direct financial impact on the Company. The Company continues to monitor the impacts of COVID-19 on the global economy and on its business operations. However, at this time, it is difficult to predict how long the potential operational impacts of COVID-19 will last or to what degree further disruption might impact the Company’s operations and financial results
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
111815000 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
77829000 usd
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
394000 usd
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
392000 usd
CY2022Q3 us-gaap Other Restricted Assets Current
OtherRestrictedAssetsCurrent
300000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
112509000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
78221000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4935 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3540 shares
atnm Accountingstandardsrecentlyissuedpolicytextblock
Accountingstandardsrecentlyissuedpolicytextblock
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Recently Adopted Accounting Pronouncements – </b>In May 2021, FASB issued ASU 2021-04, <i>Earnings Per Share (topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation – Stock Compensation (Topic 718) and Derivatives and Hedging – Contracts in an Entity’s Own Equity (Subtopic 815-40) – Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</i>, which provides guidance of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange as (1) an adjustment to equity and, if so, the related earnings per share (EPS) effects, if any, or (2) an expense and, if so, the manner and pattern of recognition. The amendments in this ASU are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022 and the standard did not have a material effect on the Company’s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2021, the FASB issued ASU 2021-10, <i>Government Assistance (Topic 832), Disclosures by Business Entities about Government Assistance</i>, which provides guidance on disclosure requirements to entities other than not-for-profit entities about transaction with a government that are accounted for by applying a grant or contribution accounting model by analogy. ASU 2021-10 requires an entity to make annual disclosures related to (1) the nature of the transactions and the related accounting policy used to account for the government transactions, (2) quantification and disclosure of amounts related to the government transactions included in balance sheet and income statement financial statement line items, and (3) significant terms and conditions of the government transactions, including commitments and contingencies. The amendments of ASU 2021-10 are effective January 1, 2022, including interim periods. The Company adopted this standard effective January 1, 2022, and the standard did not have a material impact on the Company’s financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2012Q2 atnm Milestone Payment
MilestonePayment
1000000 usd
CY2012Q2 atnm Description Of Royalty Payment To Related Party
DescriptionOfRoyaltyPaymentToRelatedParty
Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC.
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
5 years 2 months
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2027-07-30
us-gaap Lease Cost
LeaseCost
600000 usd
atnm Number Of Operating Lease
NumberOfOperatingLease
2 pure
atnm Number Of Finance Lease
NumberOfFinanceLease
2 pure
atnm Addition Space For Operating Lease
AdditionSpaceForOperatingLease
1 pure
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
206000 usd
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
93000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
440000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
279000 usd
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
14000 usd
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
20000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
54000 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
61000 usd
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7000 usd
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
14000 usd
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
22000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
56000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
68000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
302000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
282000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
2000 usd
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
7000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
48000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
63000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2605000 usd
atnm Schedule Or Description Of Weighted Average Term
ScheduleOrDescriptionOfWeightedAverageTerm
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted average remaining lease term:</span></td> <td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating leases</span></td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8 years</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance Leases</span></td> <td> </td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3 year</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
atnm Schedule Of Weighted Average Discount Rate
ScheduleOfWeightedAverageDiscountRate
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>Weighted average discount rates:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left">Operating leases</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">4.8</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Finance Leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8.0</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"> </p>
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.048 pure
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.08 pure
CY2022Q3 atnm Recognition Of Deferred Revenue1
RecognitionOfDeferredRevenue1
0 usd
atnm Recognition Of Deferred Revenue1
RecognitionOfDeferredRevenue1
900000 usd
CY2021Q3 atnm Recognition Of Deferred Revenue1
RecognitionOfDeferredRevenue1
0 usd
atnm Recognition Of Deferred Revenue1
RecognitionOfDeferredRevenue1
900000 usd
CY2022Q3 atnm Revenue Recognized
RevenueRecognized
0 usd
atnm Revenue Recognized
RevenueRecognized
100000 usd
atnm Revenue Recognized
RevenueRecognized
200000 usd
CY2021Q3 atnm Revenue Recognized
RevenueRecognized
200000 usd
CY2022Q2 atnm Upfront Payment
UpfrontPayment
35000000 usd
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
900000 usd
CY2022Q3 atnm Longterm License Revenue Deferred
LongtermLicenseRevenueDeferred
35000000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1362 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.45
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P8Y8M8D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1885 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.99
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.06
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3192 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.06
atnm Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P9Y10D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5377000 usd
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
638 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
17.94
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y5M4D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
397000 usd
CY2022Q3 atnm Class Of Warrants Shares Expired
ClassOfWarrantsSharesExpired
600000 shares
CY2017Q3 atnm Underwritten Offering Shares
UnderwrittenOfferingShares
700000 shares
CY2017Q3 atnm Warrants To Purchase Shares Of Common Stock
warrantsToPurchaseSharesOfCommonStock
600000 shares
CY2017Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
22.5
atnm Exercisable Period Years
ExercisablePeriodYears
P5Y
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
31.5
CY2022Q3 atnm Shares Of Common Stock Value
SharesOfCommonStockValue
300000 usd
CY2022Q3 atnm Net Proceeds
NetProceeds
2700000 usd
us-gaap Interest Paid Net
InterestPaidNet
usd
atnm Acquisition Of Equipment Financed By Security Deposit
AcquisitionOfEquipmentFinancedBySecurityDeposit
usd
CY2021Q4 us-gaap Other Restricted Assets Current
OtherRestrictedAssetsCurrent
usd
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20060315 shares
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
usd
CY2021Q4 atnm Longterm Operating Lease Obligations Noncurrent
LongtermOperatingLeaseObligationsNoncurrent
usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 atnm Longterm License Revenue Deferred
LongtermLicenseRevenueDeferred
usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001388320

Files In Submission

Name View Source Status
0001213900-22-072371-index-headers.html Edgar Link pending
0001213900-22-072371-index.html Edgar Link pending
0001213900-22-072371.txt Edgar Link pending
0001213900-22-072371-xbrl.zip Edgar Link pending
atnm-20220930.xsd Edgar Link pending
f10q0922ex31-1_actiniumphar.htm Edgar Link pending
f10q0922ex31-2_actiniumphar.htm Edgar Link pending
atnm-20220930_cal.xml Edgar Link unprocessable
atnm-20220930_def.xml Edgar Link unprocessable
atnm-20220930_pre.xml Edgar Link unprocessable
atnm-20220930_lab.xml Edgar Link unprocessable
f10q0922ex32-1_actiniumphar.htm Edgar Link pending
f10q0922ex32-2_actiniumphar.htm Edgar Link pending
f10q0922_actiniumpharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
f10q0922_actiniumpharma_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable